BlackRock, Inc. 13D and 13G filings for Heron Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Heron Therapeutics, Inc. HRTX |
BlackRock Inc. BLK |
8,534,567 5.600% |
0 (Unchanged) |
Filing |
| 2024-10-24 2:02 pm Purchase |
2024-09-30 | 13G | Heron Therapeutics, Inc. HRTX |
BlackRock Inc. BLK |
8,534,567 5.600% |
1,497,253 (+21.28%) |
Filing |
| 2023-12-06 4:47 pm Sale |
2023-11-30 | 13G | Heron Therapeutics, Inc. HRTX |
BlackRock Inc. BLK |
7,037,314 4.700% |
-2,613,395 (-27.08%) |
Filing |
| 2023-02-03 4:27 pm Purchase |
2022-12-31 | 13G | Heron Therapeutics, Inc. HRTX |
BlackRock Inc. BLK |
9,650,709 8.100% |
1,968,508 (+25.62%) |
Filing |
| 2022-02-01 5:08 pm Purchase |
2021-12-31 | 13G | Heron Therapeutics, Inc. HRTX |
BlackRock Inc. BLK |
7,682,201 7.500% |
795,269 (+11.55%) |
Filing |
| 2021-01-29 09:56 am Purchase |
2020-12-31 | 13G | Heron Therapeutics, Inc. HRTX |
BlackRock Inc. BLK |
6,886,932 7.600% |
1,118,730 (+19.39%) |
Filing |